Titre : Bandes oligoclonales

Bandes oligoclonales : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit Disorder with Hyperactivity
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Bandes oligoclonales : Questions médicales les plus fréquentes", "headline": "Bandes oligoclonales : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Bandes oligoclonales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-15", "dateModified": "2025-04-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Bandes oligoclonales" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Marqueurs biologiques", "url": "https://questionsmedicales.fr/mesh/D015415", "about": { "@type": "MedicalCondition", "name": "Marqueurs biologiques", "code": { "@type": "MedicalCode", "code": "D015415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.101" } } }, "about": { "@type": "MedicalCondition", "name": "Bandes oligoclonales", "alternateName": "Oligoclonal Bands", "code": { "@type": "MedicalCode", "code": "D043025", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Luisa María Villar", "url": "https://questionsmedicales.fr/author/Luisa%20Mar%C3%ADa%20Villar", "affiliation": { "@type": "Organization", "name": "Ramon y Cajal Hospital of Madrid, Spain." } }, { "@type": "Person", "name": "Wei Qiu", "url": "https://questionsmedicales.fr/author/Wei%20Qiu", "affiliation": { "@type": "Organization", "name": "Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: qiuwei120@vip.163.com." } }, { "@type": "Person", "name": "Alexander Y Lau", "url": "https://questionsmedicales.fr/author/Alexander%20Y%20Lau", "affiliation": { "@type": "Organization", "name": "Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: alexlau@cuhk.edu.hk." } }, { "@type": "Person", "name": "Hongjun Hao", "url": "https://questionsmedicales.fr/author/Hongjun%20Hao", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Neuroimmunology Laboratory, Peking University First Hospital, Beijing, China." } }, { "@type": "Person", "name": "Carmen M Cabrera", "url": "https://questionsmedicales.fr/author/Carmen%20M%20Cabrera", "affiliation": { "@type": "Organization", "name": "Immunology Section, University General Hospital of Ciudad Real, Ciudad Real, Spain; Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain. Electronic address: carmenmcabrera@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Identification of attention deficit hyperactivity disorder with deep learning model.", "datePublished": "2023-05-16", "url": "https://questionsmedicales.fr/article/37191853", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s13246-023-01275-y" } }, { "@type": "ScholarlyArticle", "name": "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/36971690", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD009885.pub3" } }, { "@type": "ScholarlyArticle", "name": "Altered somatosensory processing in adult attention deficit hyperactivity disorder.", "datePublished": "2024-08-13", "url": "https://questionsmedicales.fr/article/39138461", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12888-024-06002-9" } }, { "@type": "ScholarlyArticle", "name": "Parental perspectives on attention-deficit/hyperactivity disorder treatments for children.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35695509", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/13591045221108836" } }, { "@type": "ScholarlyArticle", "name": "Potential Inflammatory Biomarker in Patients with Attention Deficit Hyperactivity Disorder.", "datePublished": "2022-10-27", "url": "https://questionsmedicales.fr/article/36361835", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms232113054" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Marqueurs biologiques", "item": "https://questionsmedicales.fr/mesh/D015415" }, { "@type": "ListItem", "position": 4, "name": "Bandes oligoclonales", "item": "https://questionsmedicales.fr/mesh/D043025" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Bandes oligoclonales - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Bandes oligoclonales", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Bandes oligoclonales", "description": "Comment détecte-t-on les bandes oligoclonales ?\nQuelles maladies sont associées aux bandes oligoclonales ?\nQuel est le rôle des bandes oligoclonales dans le diagnostic ?\nLes bandes oligoclonales sont-elles toujours présentes dans les maladies ?\nQuel test est utilisé pour analyser les bandes oligoclonales ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Bandes oligoclonales", "description": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?\nLes bandes oligoclonales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les maladies ?\nLes symptômes sont-ils toujours présents avec des bandes oligoclonales ?\nQuels tests neurologiques complètent l'analyse des bandes ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Bandes oligoclonales", "description": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?\nQuels facteurs de risque sont associés aux maladies neurologiques ?\nL'alimentation influence-t-elle le risque de maladies neurologiques ?\nLe stress a-t-il un impact sur ces maladies ?\nDes vaccinations peuvent-elles prévenir ces maladies ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Bandes oligoclonales", "description": "Quel traitement est recommandé pour les maladies associées ?\nLes bandes oligoclonales nécessitent-elles un traitement direct ?\nQuels médicaments sont utilisés pour la sclérose en plaques ?\nLes traitements sont-ils efficaces contre les bandes ?\nY a-t-il des traitements expérimentaux pour ces conditions ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Bandes oligoclonales", "description": "Quelles complications peuvent survenir avec la sclérose en plaques ?\nLes bandes oligoclonales entraînent-elles des complications ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme des maladies neurologiques ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Bandes oligoclonales", "description": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?\nLe tabagisme est-il un facteur de risque ?\nL'exposition à des virus influence-t-elle le risque ?\nLe climat joue-t-il un rôle dans le risque de sclérose en plaques ?\nL'activité physique peut-elle réduire le risque ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les bandes oligoclonales ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont détectées par électrophorèse du liquide céphalorachidien." } }, { "@type": "Question", "name": "Quelles maladies sont associées aux bandes oligoclonales ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont souvent liées à la sclérose en plaques et d'autres maladies neurologiques." } }, { "@type": "Question", "name": "Quel est le rôle des bandes oligoclonales dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles aident à confirmer des diagnostics neurologiques en indiquant une réponse immunitaire." } }, { "@type": "Question", "name": "Les bandes oligoclonales sont-elles toujours présentes dans les maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur présence n'est pas systématique et dépend de la maladie et de son stade." } }, { "@type": "Question", "name": "Quel test est utilisé pour analyser les bandes oligoclonales ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'électrophorèse sur gel est couramment utilisée pour analyser les bandes oligoclonales." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques comme des troubles de la vision ou des engourdissements." } }, { "@type": "Question", "name": "Les bandes oligoclonales causent-elles des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles sont un indicateur de maladie, mais ne causent pas de symptômes directement." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les maladies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon la maladie sous-jacente, comme la sclérose en plaques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents avec des bandes oligoclonales ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Pas nécessairement, certaines personnes peuvent avoir des bandes sans symptômes visibles." } }, { "@type": "Question", "name": "Quels tests neurologiques complètent l'analyse des bandes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des IRM et des tests neurologiques peuvent compléter l'analyse des bandes oligoclonales." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés aux maladies neurologiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le sexe et des antécédents familiaux peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de maladies neurologiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut réduire le risque, mais des études sont nécessaires." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur ces maladies ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver les symptômes, mais son rôle exact dans la maladie est complexe." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles prévenir ces maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les maladies associées." } }, { "@type": "Question", "name": "Quel traitement est recommandé pour les maladies associées ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements varient, mais incluent souvent des immunomodulateurs pour la sclérose en plaques." } }, { "@type": "Question", "name": "Les bandes oligoclonales nécessitent-elles un traitement direct ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles ne nécessitent pas de traitement direct, mais indiquent une maladie à traiter." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour la sclérose en plaques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme l'interféron et le natalizumab sont couramment utilisés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces contre les bandes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements visent la maladie sous-jacente, pas les bandes elles-mêmes." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour ces conditions ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour certaines maladies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la sclérose en plaques ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles de la mobilité, de la vision et des fonctions cognitives." } }, { "@type": "Question", "name": "Les bandes oligoclonales entraînent-elles des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles ne causent pas de complications directement, mais indiquent une maladie à risque." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en limitant les activités quotidiennes et sociales." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme des maladies neurologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent inclure des handicaps physiques et cognitifs." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe féminin, et des antécédents familiaux de la maladie." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de développer des maladies neurologiques." } }, { "@type": "Question", "name": "L'exposition à des virus influence-t-elle le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le climat joue-t-il un rôle dans le risque de sclérose en plaques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le risque est plus élevé dans les régions éloignées de l'équateur." } }, { "@type": "Question", "name": "L'activité physique peut-elle réduire le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Une activité physique régulière peut contribuer à réduire le risque de maladies neurologiques." } } ] } ] }

Sources (10000 au total)

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated psychiatric disorders in childhood. Typically, children and adolescents with ADHD find it difficult to... To assess the beneficial and harmful effects of methylphenidate for children and adolescents with ADHD.... We searched CENTRAL, MEDLINE, Embase, three other databases and two trials registers up to March 2022. In addition, we checked reference lists and requested published and unpublished data from manufac... We included all randomised clinical trials (RCTs) comparing methylphenidate versus placebo or no intervention in children and adolescents aged 18 years and younger with a diagnosis of ADHD. The search... Two review authors independently conducted data extraction and risk of bias assessment for each trial. Six review authors including two review authors from the original publication participated in the... We included 212 trials (16,302 participants randomised); 55 parallel-group trials (8104 participants randomised), and 156 cross-over trials (8033 participants randomised) as well as one trial with a p... methylphenidate versus placebo or no intervention may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.74, 95% confidence interval (CI) -0.88 to -0.61; I² = 38%; 21 trials; 1... methylphenidate may cause more adverse events considered non-serious versus placebo or no intervention (RR 1.23, 95% CI 1.11 to 1.37; I² = 72%; 35 trials 5342 participants; very low-certainty evidence... The majority of our conclusions from the 2015 version of this review still apply. Our updated meta-analyses suggest that methylphenidate versus placebo or no-intervention may improve teacher-rated ADH...

Altered somatosensory processing in adult attention deficit hyperactivity disorder.

Tactile sensitivity and sensory overload in ADHD are well-documented in clinical-, self-, and parent- reports, but empirical evidence is scarce and ambiguous and focuses primarily on children. Here, w... Somatosensory evoked potential (SEP) amplitudes were measured in 27 adults with ADHD and 24 controls during four conditions (rest, stroking of the own arm, stroking of the arm by a researcher, and str... Participants with ADHD self-reported greater tactile sensitivity and ADHD symptom severity than controls and received higher scores on the Qb-test. These values correlated with one another. ADHD parti... We find that ADHD symptomatology and touch sensitivity are directly linked, using both self-reports and experimental measures. We also find evidence of tactile sensory overload in ADHD, and an indicat...

Sensory Processing in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

The aim is to assess the sensory processing difficulties in children and adolescents with ADHD.... In all, 38 ADHD children of the age group 6-14 years and 34 age- and gender-matched typically developing controls were included in the study. Sensory processing was assessed on Child Sensory Profile-2... A significantly higher sensory processing difficulties were seen in children with ADHD than typically developing controls. There were positive correlations between the scores of Child sensory profile ... Sensory problems were common in children with ADHD and add to the functional impairments....

Preterm postnatal complications and risk of attention-deficit/hyperactivity disorder.

To investigate the association between the risk of attention-deficit/hyperactivity disorder (ADHD) and preterm birth and determine how postnatal complications in children born preterm is associated wi... This population-based cohort study used data from the Hong Kong electronic medical records. We followed 359 614 children (48% female; 6-17 years old, mean 11 years 7 months, SD 3 years 2 months) born ... The risk of ADHD was 4.0% in children born at term and 5.1% in children born preterm. The odds ratio for ADHD was 2.08 (95% confidence interval [CI] 1.64-2.64) for children born extremely preterm, 1.6... Children born preterm in all subcategories, from extremely preterm to late preterm, have increased risk of ADHD. Early respiratory infection partially mediates the risk of ADHD in children born preter...